China | Announcement on "Determination of Tacrolimus and Pimecrolimus in Cosmetics" Supplemental Inspection Method (Announcement No. 89 of 2023)

In accordance with the "Regulations on the Supervision and Administration of Cosmetics," the National Medical Products Administration (NMPA) has approved the "Determination of Tacrolimus and Pimecrolimus in Cosmetics" as a supplemental inspection method for cosmetics and is now releasing it for implementation.

This announcement aims to strengthen the supervision and quality control of cosmetics in the market, especially concerning the presence of Tacrolimus and Pimecrolimus, which are substances of concern in cosmetics.

The full details and guidelines for the implementation of this method can be found in the attached document titled "Determination of Tacrolimus and Pimecrolimus in Cosmetics (BJH 202301)".